The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Power List / 2026 / Power List / Rajal B. Shah

Rajal B. Shah

Dr. Charles T. Ashworth Professor of Pathology, University of Texas Southwestern Medical School, Dallas, Texas, USA; and Immediate Past President, Genitourinary Pathology Society (GUPS).

  • Q&A

About Rajal B. Shah

What’s the biggest challenge facing your specialty right now, and how are you addressing it via leadership?

Consistent, evidence-based recommendations underpin standardised reporting and clear communication between pathologists and clinicians. When international guidance differs, however, diagnostic consistency and patient management may be affected.

In 2019, the genitourinary pathology community faced this challenge when two international organisations – the Genitourinary Pathology Society (GUPS) and the International Society of Urological Pathology (ISUP) – issued conflicting recommendations on whether intraductal carcinoma of the prostate should be incorporated into the Gleason score for invasive prostate cancer. This disagreement created prolonged uncertainty for pathologists and clinicians, with potential implications for patient management.

At the same time, debate intensified over whether Grade Group 1 prostate cancer, which is often indolent, should be reclassified as “non-cancer” to reduce overtreatment.

When I became President of GUPS in 2024, I recognised that resolving these longstanding issues required collaboration beyond individual institutions. Joint guidance from GUPS and ISUP was essential to restoring consistency, so I initiated discussions with the President of ISUP.

To address the controversy surrounding intraductal carcinoma of the prostate, I co-led a joint consultation involving 32 international experts from both organisations. We used a modified Delphi process that included iterative discussions, predefined consensus thresholds, and input from the wider professional community. The panel reached consensus on an issue that had divided the field for five years. The resulting practice recommendations were recently published in Histopathology and may inform future guidance from other organisations, including the WHO and the College of American Pathologists.

Simultaneously, addressing the debate surrounding the renaming of GG1 prostate cancer demanded rigorous academic leadership. I co-led and authored a high-impact white paper addressing this critical issue, published in European Urology and the full version in The American Journal of Surgical Pathology. This landmark publication will provide the global medical community with a pragmatic, clear, and scientifically balanced pathway forward.

True leadership is defined by the ability to build bridges where there is deep discord. By aligning the two premier societies in our field, this initiative successfully replaced years of professional confusion with unified practicing guidelines. I am immensely proud to have guided GUPS and the broader urological pathology community toward a collaborative future that directly optimizes standardized reporting and elevates the quality of patient care worldwide.

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

Explore Pathology Infectious Disease

The Viral Frontier

January 23, 2024

1 min read

Explore Pathology Genetics and epigenetics

Breathing New Life into Diagnostics

January 22, 2024

6 min read

Explore Pathology Analytical science

Opening a Window into Brain Trauma

January 18, 2024

4 min read

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.